The Regional Centers and the Network Units of the Project have investigated/recorded a large number of outbreaks of FMD throughout the country. This has helped in the understanding of the region-wise prevalence of different serotypes of FMD virus from time to time and associated epidemiology, and accumulated epidemiological data helped in planning and launching of FMD Control Programme by the Government of India (DADF) in 2003-04. Further, the centers are involving in attending FMD outbreaks, collection of clinical materials and epidemiological. ICAR is the technical arm of FMD-CP and AICRP on FMD is been actively involved in seromonitoring to assess the vaccine effectiveness under FMD-CP and also in sero-surveillance against FMD. Last two years, under Foot and Mouth Disease Control Programme (FMD-CP) 1,33,129 serum samples were tested by LPBE for herd immunity. Under National Sero-surveillance 52,997 randomly collected serum samples were tested by LPBE in Random Serosurveillance Programme for determination of antibody level against structural proteins. 91,660 serum sample were tested by r3AB3 NSP-ELISA (DIVA ELISA) for assessing NSP-antibody response. 112 virus isolates were added to the National Virus Repository. 135 virus field isolates were subjected to complete region sequence analysis. Under Tribal Sub Plan, Free FMD vaccination cum treatment camps, Exposure visits in tribal areas and distribution of goat kids, piglets camps were organized.
Progress of Vaccination Programme under FMD-CP
Percent animals showing post vaccinal antibody titers of ≥1.8 log10 against FMD virus (2003-04, 54 districts)
| Phase | Type O | Type A | Type Asia 1 | |||
| Pre-vac | Post-vac | Pre-vac | Post-vac | Pre-vac | Post-vac | |
| I | 27.3 | 53.5 | 22.0 | 49.5 | 23.8 | 57.6 |
| II | 36.7 | 60.2 | 23.3 | 48.4 | 36.8 | 63.5 |
| III | 43.7 | 64.3 | 43.7 | 61.5 | 39.1 | 62.6 |
| IV | 41.2 | 62.3 | 42.4 | 67.5 | 36.2 | 61.1 |
| V | 38.0 | 39.3 | 46.3 | 65.6 | 40.8 | 59.4 |
| VI | 38.9 | 67.9 | 46.6 | 73.9 | 36.8 | 62.6 |
| VII | 39.7 | 68.5 | 39.4 | 67.1 | 35.1 | 62.8 |
| VIII | 42.3 | 68.7 | 37.0 | 58.6 | 33.5 | 57.0 |
| IX | 63.7 | 85.6 | 52.0 | 73.3 | 52.6 | 73.0 |
| X | 63.4 | 87.4 | 50.6 | 74.7 | 48.9 | 76.7 |
| XI | 44.1 | 57.8 | 37.8 | 51.5 | 39.3 | 59.3 |
| XII | 36.6 | 55.3 | 31.8 | 54.9 | 30.0 | 39.3 |
| XIII | 44.0 | 48.8 | 26.8 | 41.4 | 30.4 | 46.3 |
| XIV | 48.2 | 67.7 | 45.5 | 58.9 | 47.3 | 52.7 |
| XV | 46.5 | 71.6 | 50.1 | 76.0 | 54.4 | 78.5 |
| XVI | 47.8 | 77.0 | 52.5 | 78.4 | 57.0 | 85.9 |
| XVII | 66.6 | 80.6 | 63.4 | 82.8 | 67.3 | 84.8 |
| XVIII | 75.1 | 89.0 | 57.0 | 78.6 | 74.0 | 87.1 |
| XIX | 75.5 | 92.8 | 69.7 | 93.4 | 73.4 | 96.0 |
| XX | 75.8 | 94.8 | 71.0 | 93.6 | 87.2 | 97.0 |
Percent animals showing post vaccinal antibody titers of ≥1.8 log10 against FMD virus (2010-16, 315 districts) (Extended FMDCP)
| Phase | Type O | Type A | Type Asia 1 | |||
| Pre-vac | Post-vac | Pre-vac | Post-vac | Pre-vac | Post-vac | |
| I | 33.4 | 65.3 | 21.4 | 50.7 | 10.9 | 40.7 |
| II | 37.5 | 66.5 | 23.5 | 46.3 | 20.5 | 38.2 |
| III | 36.5 | 63.1 | 28.3 | 52.1 | 34.2 | 56.1 |
| IV | 39.4 | 66.8 | 50.5 | 75.3 | 53.7 | 77.8 |
| V | 45.9 | 74.1 | 57.3 | 81.1 | 60.4 | 84.4 |
| VI | 64.5 | 90.0 | 57.4 | 86.0 | 65.0 | 87.8 |
| VII | 77.7 | 93.2 | 73.6 | 89.5 | 80.2 | 89.7 |
| VIII | 84.2 | 95.1 | 76.8 | 94.5 | 88.1 | 96.2 |
| IX | 84.7 | 96.2 | 78.8 | 94.6 | 85.2 | 97.1 |